a public good project by the
Synthesis
Company
of California

© 2026

René González | doi.page

0 works0 citations0 h-index

René González

University of Miami(US)Sylvester Comprehensive Cancer Center(US)

Publications by Year

Research Areas

Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management

Most-Cited Works

→ Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
→ Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
→ Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
→ Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
→ Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
→ Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
→

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012)

2,141 cited

→ Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial(2015)1,554 cited

→ Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial(2018)1,385 cited

→ RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors(2012)1,015 cited